ClinicalTrials.gg
Not yet recruitingNCT06669403Updated Sep 15, 2025

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

A Phase 1 interventional study of OPT101 and Placebo in Sepsis and Community Acquired Pneumonia (CAP), sponsored by Op-T LLC. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Op-T LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 517 studies in Sepsis with a site in United States — 75 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.

Planned enrollment
232nd of 310
26 · median 84
Started
2025
with 21 others
Phase 1
32 of 517
3 open now
Primary completion
2026-04
later than 19 of 98 live
Registered
464th of 517
by date

Among the 517 studies in Sepsis with a site in United States, this one is the 232nd largest by planned enrollment of the 310 interventional ones that give a count, is one of 22 that started in 2025, is one of 32 in phase 1, reaches primary completion later than 19 of the 98 other live ones, and was the 464th registered.

Sepsis

2,418 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

75 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 319 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 517 studies in Sepsis with a site in United States, or all of them as a file.
02

Study summary

OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis.

This study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.

03

Conditions studied

  • Sepsis
  • Community Acquired Pneumonia (CAP)

Keywords

  • Sepsis
  • Community Acquired Pneumonia (CAP)
  • Immunomodulator
  • OPT101
  • Op-T LLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are able and willing to give signed (legally authorized representative can provide informed consent if needed).
  2. ≥18 years old;
  3. Patients hospitalized for clinically suspected community acquired pneumonia (CAP), defined as the occurrence of (within 48h from hospital admission) at least 1 of the following signs:

    • respiratory rate > 30 breaths/min;
    • fever (> 38.0°C or > 100.4° F);
    • leukopenia (≤ 4,000 WBC/mm3 or leukocytosis (≥ 12,000 WBC/mm3);
    • adults ≥ 70 years of age; altered mental status with no other recognized cause;

    AND at least 1 of the following:

    • New onset of purulent sputum or change in character of sputum or increased respiratory secretions;
    • New onset or worsening cough, or dyspnea, or tachypnea;
    • Rales or bronchial breath sounds; AND Radiologic imaging (chest x-ray or CT scan) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation AND SpO2 \<92% at room air, or PaO2/FiO2 (or SpO2/FiO2) \<300; recorded on one episode
  4. Need for non-invasive supplemental oxygen (nasal cannula, simple mask, venturi or reservoir cannula/mask or heated high flow nasal cannula oxygen.
  5. Females of who are sexually active must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of :

    • Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last OPT101 dose
    • A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last OPT101 dose
    • A male sexual partner who agrees to use a male condom with spermicide
    • A sterile sexual partner

Exclusion criteria

Exclusion Criteria:

  1. Need for endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at time of study screening
  2. ≥ 450 msec on screening
  3. Hepatic dysfunction: or AST > 5 ; history of chronic hepatic disease (defined with score ≥ 12)
  4. Recent or active hepatitis A infection; test positive or have been treated for , , or infection; evidence of active or untreated latent TB; a recent history of recurrent herpes zoster and/or opportunistic infection; and/or taking medication.
  5. Renal dysfunction: estimated (eGFR) \<50 mL/min/1.73 m2, or need for hemodialysis or hemofiltration
  6. Current use of >2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC \< local LLN), solid organ or bone marrow transplant recipients)
  7. Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period
  8. Anticipated discharge from the hospital or transfer to another hospital within 48 hours of screening
  9. Allergy to OPT101or any component of OPT101 formulation
  10. Participation in other interventional clinical trials
  11. Pregnancy:

    • positive or missing pregnancy test before first drug intake or day 1
    • pregnant or lactating women;
    • Women of and fertile men who do not agree to use at least one primary form of for the duration of the study
  12. Current hospital stay >72h
  13. Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism
  14. Weight is over 250lbs
  15. Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study. The Principal Investigator should make this determination in consideration of the patient's medical history and current clinical condition.

    -

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
26 participants (estimated)

Study arms

  • Placebo comparator
    0.9% Sodium Chloride Injection USP

    Placebo will be 50mL normal saline (Sodium Chloride), USP sterile solution provided in a 50mL pre-packaged Intravenous (IV) bag.

    Other: Placebo

  • Experimental
    OPT101

    OPT101 (15-mer peptide) will be provided across 2 cohorts at 1.1 (cohort 1) and 2.8 mg/kg (cohort 2) doses . On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.

    Drug: OPT101

Interventions

  • DrugOPT101

    OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.

  • OtherPlacebo

    0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.

    Also known as: Placebeo

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Treatment emergent adverse events will be recorded and assessed by CTCAE v4.0

    Time frame: 30 days

  2. Incidence of serious adverse events (SAEs)

    SAEs will be recorded and assessed by CTCAE v4.0

    Time frame: 30 days

  3. Incidence of TEAEs leading to study drug discontinuation

    Time frame: 30 days

  4. Incidence and characteristics of presumed infusion reactions

    Recorded as an adverse event

    Time frame: 30 days

Secondary outcomes

  1. To measure the serum pharmacokinetics of OPT101

    Serum concentrations of OPT101 to determine AUCO-24

    Time frame: 30 days

  2. To measure the serum pharmacokinetics of OPT101

    Serum concentrations of OPT101 to determine Cmax

    Time frame: 30 days

  3. To measure the serum pharmacokinetics of OPT101

    Serum concentrations of OPT101 to determine Tmax

    Time frame: 30 days

  4. To measure the serum pharmacokinetics of OPT101

    Serum concentrations of OPT101 to determine t1/2

    Time frame: 30 days

  5. To measure the serum pharmacokinetics of OPT101

    Serum concentrations of OPT101 to determine Vz/F

    Time frame: 30 days

Other outcomes

  1. To observe the changes in degree of sepsis via Pneumonia Severity Index (PSI)

    Pneumonia Severity Index (PSI) predicts the need for hospitalization for people with Community Acquired Pneumonia (CAP). Patients are ranked by Risk Class (I , II, III, IV or V). Patients with CAP categorized as Risk Class of I and II can be treated at home. Patients with CAP categorized as Risk Class III may be treated at home or may require a short hospital stay. Patients with CAP categorized as Risk Class of IV and V require hospitalization.

    Time frame: 30 days

  2. To observe the changes in degree of sepsis via Sequential Organ Failure Assessment (SOFA) score

    SOFA grading, minimum value is 0 (normal) and maximum value is 4 (highest degree of dysfunction/failure). The higher the score, the worse the outcome.

    Time frame: 30 days

  3. To observe the changes in degree of sepsis via Cytokine Release Syndrome (CRS) grading

    CRS is graded from Grade 1 to Grade 4. Grade 1 is the best outcome and Grade 4 is the worst outcome in terms of change in degree of sepsis. CRS parameters used for grading include fever, hypotension and hypoxia.

    Time frame: 30 days

  4. Evaluate Pharmacodynamic Effects of OPT101

    Quantitation of Th40 to Treg ratio

    Time frame: 30 days

  5. Evaluate Pharmacodynamic Effects of OPT101

    Quantitation of peripheral blood B cells

    Time frame: 30 days

  6. Evaluate Pharmacodynamic Effects of OPT101

    Quantitation of macrophages

    Time frame: 30 days

  7. Evaluate Pharmacodynamic Effects of OPT101

    Quantitation inflammatory biomarkers

    Time frame: 30 days

  8. Evaluate Pharmacodynamic Effects of OPT101

    Quantitation of Th40 cells,

    Time frame: 30 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Apr 2026, 4 months later.

Of 32 phase 1 interventional studies under Sepsis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Nov 1, 2024
StartEst.
Dec 2025
Primary completionEst.
Apr 2026
CompletionEst.
May 2026
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06669403
Lead sponsor
Op-T LLC
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Dec 2025 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Sep 15, 2025

Study contacts

Lisa M Boswell, MS
Contact
lmboswell@live.com
720-315-0198
Marc L Giles, BS
Contact
mg@op-t.com
720-315-0198
Herbert B Slade, MD FAAAAI
study director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OPT101

Start the discussion